Induction Chemotherapy for the Individualized Treatment of Hypopharyngeal Cancer with Oesophageal Invasion: A Retrospective Cohort Study

Abstract Background: This study aimed to evaluate the potential for induction chemotherapy to be an indicator for the management of advanced hypopharyngeal carcinoma with cervical oesophageal invasion.Methods: Sixty-eight patients (admitted to our department between February 2003 and November 2016) with stage IVB hypopharyngeal cancer with cervical oesophageal invasion were retrospectively analysed. Patients were divided into two groups depending on the treatment they selected following an explanation they received on the different treatments. Group A patients received induction chemotherapy and had (1) complete or partial remission following chemotherapy combined with radiotherapy or concurrent chemoradiotherapy or (2) stable disease following chemotherapy combined with surgery. Group B patients underwent surgery and received adjuvant radiotherapy or concurrent chemoradiotherapy following surgery. Survival analyses were performed using the Kaplan–Meier method, differences between the two groups were tested using the log-rank test, and the laryngeal and oesophageal retention rates were compared using the cross-tabulation test. Results: The 3- and 5-year overall survival rates of patients in Group A were 22.86% and 11.43%, respectively; in Group B, the rates were 24.25% and 6.06%, respectively (P > 0.05 for all). The laryngeal retention rates in Group A and B patients were 40% and 0%, respectively, whereas the oesophageal retention rates in Group A and B patients were 74.3% and 27.3%, respectively (P < 0.01 for all). There was no statistically significant difference in the incidence of postoperative complications between the two groups (Group A: 8.6%, Group B: 12.1%, P > 0.05). Conclusions: For patients with advanced hypopharyngeal cancer with cervical oesophageal invasion, induction chemotherapy could be the appropriate first choice for individualized treatment to ensure laryngeal and oesophageal cancer preservation.

Download Full-text

Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study

10.21203/rs.3.rs-37170/v2 ◽

2020 ◽

Author(s):

Tian-qiao Huang ◽

Ru Wang ◽

Ju-gao Fang ◽

Shi-zhi He ◽

Qi Zhong ◽

...

Keyword(s):

Induction Chemotherapy ◽

Concurrent Chemoradiotherapy ◽

Retention Rates ◽

Rank Test ◽

Hypopharyngeal Carcinoma ◽

First Choice ◽

Significant Difference ◽

Group A ◽

Group B ◽

Individualised Treatment

Abstract Background: The aim of this study was to evaluate the potential of induction chemotherapy as an indicator of the management of advanced hypopharyngeal carcinoma with cervical oesophageal invasion. Methods: Sixty-eight patients admitted to our hospital between February 2003 and November 2016 with stage IVB hypopharyngeal carcinoma with cervical oesophageal invasion were retrospectively analysed. Patients were divided into two groups according to the treatment they selected following an explanation of the different treatments available. Patients in Group A received induction chemotherapy and had (1) complete/partial remission following chemotherapy and radiotherapy/concurrent chemoradiotherapy or (2) stable disease following chemotherapy and surgery. Patients in Group B underwent surgery followed by adjuvant radiotherapy/concurrent chemoradiotherapy. Survival analyses were performed using the Kaplan–Meier method, and differences between the groups were evaluated using the log-rank test. Laryngeal and oesophageal retention rates were compared using the cross-tabulation test. Results: The 3- and 5-year overall survival rates were 22.86% and 11.43% in Group A and 24.25% and 6.06% in Group B, respectively (all P > 0.05). The laryngeal and oesophageal retention rates were 40.0% and 74.3% in Group A and 0.0% and 27.3% in Group B, respectively (all P < 0.01). There was no statistically significant difference in the incidence of post-operative complications between the two groups (Group A: 8.6%, Group B: 12.1%; P > 0.05). Conclusions: Induction chemotherapy may be an appropriate first choice to ensure laryngeal and oesophageal preservation in the individualised treatment of advanced hypopharyngeal carcinoma with cervical oesophageal invasion.

Download Full-text

Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study

World Journal of Surgical Oncology ◽

10.1186/s12957-020-02095-0 ◽

2020 ◽

Vol 18 (1) ◽

Author(s):

Tian-Qiao Huang ◽

Ru Wang ◽

Ju-Gao Fang ◽

Shi-Zhi He ◽

Qi Zhong ◽

...

Keyword(s):

Induction Chemotherapy ◽

Concurrent Chemoradiotherapy ◽

Retention Rates ◽

Rank Test ◽

Hypopharyngeal Carcinoma ◽

First Choice ◽

Significant Difference ◽

Group A ◽

Group B ◽

Individualised Treatment

Abstract Background This study aimed to evaluate the potential of induction chemotherapy as an indicator of the management of advanced hypopharyngeal carcinoma with cervical oesophageal invasion. Methods Sixty-eight patients admitted to our hospital between February 2003 and November 2016 with stage IVB hypopharyngeal carcinoma with cervical oesophageal invasion were retrospectively analysed. Patients were divided into two groups according to the treatment they selected following an explanation of the different treatments available. Patients in group A received induction chemotherapy and had (1) complete/partial remission following chemotherapy and radiotherapy/concurrent chemoradiotherapy or (2) stable disease following chemotherapy and surgery. Patients in group B underwent surgery followed by adjuvant radiotherapy/concurrent chemoradiotherapy. Survival analyses were performed using the Kaplan–Meier method, and differences between the groups were evaluated using the log-rank test. Laryngeal and oesophageal retention rates were compared using the cross-tabulation test. Results The 3- and 5-year overall survival rates were 22.86% and 11.43% in group A and 24.25% and 6.06% in group B, respectively (all P > 0.05). The laryngeal and oesophageal retention rates were 40.0% and 74.3% in group A and 0.0% and 27.3% in group B, respectively (all P < 0.01). There was no statistically significant difference in the incidence of post-operative complications between the two groups (group A 8.6%, group B 12.1%; P > 0.05). Conclusions Induction chemotherapy may be an appropriate first choice to ensure laryngeal and oesophageal preservation in the individualised treatment of advanced hypopharyngeal carcinoma with cervical oesophageal invasion.

Download Full-text

Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study

10.21203/rs.3.rs-37170/v3 ◽

2020 ◽

Author(s):

Tian-qiao Huang ◽

Ru Wang ◽

Ju-gao Fang ◽

Shi-zhi He ◽

Qi Zhong ◽

...

Keyword(s):

Induction Chemotherapy ◽

Concurrent Chemoradiotherapy ◽

Retention Rates ◽

Rank Test ◽

Hypopharyngeal Carcinoma ◽

First Choice ◽

Significant Difference ◽

Group A ◽

Group B ◽

Individualised Treatment

Abstract Background: This study aimed to evaluate the potential of induction chemotherapy as an indicator of the management of advanced hypopharyngeal carcinoma with cervical oesophageal invasion.Methods: Sixty-eight patients admitted to our hospital between February 2003 and November 2016 with stage IVB hypopharyngeal carcinoma with cervical oesophageal invasion were retrospectively analysed. Patients were divided into two groups according to the treatment they selected following an explanation of the different treatments available. Patients in Group A received induction chemotherapy and had (1) complete/partial remission following chemotherapy and radiotherapy/concurrent chemoradiotherapy or (2) stable disease following chemotherapy and surgery. Patients in Group B underwent surgery followed by adjuvant radiotherapy/concurrent chemoradiotherapy. Survival analyses were performed using the Kaplan–Meier method, and differences between the groups were evaluated using the log-rank test. Laryngeal and oesophageal retention rates were compared using the cross-tabulation test.Results: The 3- and 5-year overall survival rates were 22.86% and 11.43% in Group A and 24.25% and 6.06% in Group B, respectively (all P > 0.05). The laryngeal and oesophageal retention rates were 40.0% and 74.3% in Group A and 0.0% and 27.3% in Group B, respectively (all P < 0.01). There was no statistically significant difference in the incidence of post-operative complications between the two groups (Group A: 8.6%, Group B: 12.1%; P > 0.05).Conclusions: Induction chemotherapy may be an appropriate first choice to ensure laryngeal and oesophageal preservation in the individualised treatment of advanced hypopharyngeal carcinoma with cervical oesophageal invasion.

Download Full-text

Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective Review

Clinical Medicine Insights Oncology ◽

10.4137/cmo.s18682 ◽

2015 ◽

Vol 9 ◽

pp. CMO.S18682 ◽

Cited By ~ 14

Author(s):

Prakash Peddi ◽

Runhua Shi ◽

Binu Nair ◽

Fred Ampil ◽

Glenn M. Mills ◽

...

Keyword(s):

Head And Neck ◽

Performance Status ◽

Cell Cancer ◽

Locally Advanced ◽

Progression Free Survival ◽

Rank Test ◽

Advanced Head ◽

Significant Difference ◽

Group A ◽

Group B

Efficacy of cisplatin versus cetuximab with radiation in locally advanced head and neck cancer (LAHNC) was evaluated. A total of 96 patients with newly diagnosed LAHNC treated at our institution between 2006 and 2011 with concurrent radiation and cisplatin (group A, n = 45), cetuximab (group B, n = 24), or started with cisplatin but switched to cetuximab because of toxicity (group C, n = 27) were reviewed. Chi-square test, analysis of variance, and log-rank test were used for analysis. The three groups had similar baseline characteristics, except for median age, T stage, albumin levels, hemoglobin levels, performance status, and comorbidities. A complete response (CR) was seen in 77%, 17%, and 67% of patients ( P < 0.001), respectively. There was no significant difference in median overall survival (OS) between groups A and C. The median OS for groups A and C was not reached (>65 months), even though it was significantly longer than median OS for group B (11.6 months; P ≤ 0.001). The 2-year OS in groups A and C is significantly higher than that in group B (70% for groups A and C, 22% for group B). There is no significant difference in progression-free survival (PFS) between groups A and C. The median PFS for these groups was not reached (>62 months), and is significantly longer than that for group B (4.3 months; P ≤ 0.001). The 2-year PFS of group A (67%) and group C (76%) was significantly longer than that of group B (20%). Cisplatin with radiation appears to be more efficacious even in suboptimal dosing than cetuximab with radiation in LAHNC but the two groups were not well matched.

Download Full-text

Distance from the anal verge as an indirect measure to predict response to anti-EGFR therapy in left side metastatic colon cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e15153 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e15153-e15153

Author(s):

Daniela Pezzutti DOMINGUES Armentano ◽

Mariana Ribeiro Monteiro ◽

Raphael Araujo ◽

Renata Arakelian ◽

Paula Freire Cardoso ◽

...

Keyword(s):

Anal Verge ◽

Tumor Location ◽

Response To Therapy ◽

Rank Test ◽

Metastatic Colon Cancer ◽

Indirect Measure ◽

Colon Cancers ◽

Significant Difference ◽

Group A ◽

Group B

e15153 Background: Right and left sided colon cancers (RC, LC) differ with respect to biology and response to therapy. Several retrospective analyses have assessed the clinical effect of epidermal growth fator receptor (EGFR) targeted agents in patients with metastatic CRC (mCRC) according to the primary tumor location. Differentiating only right from left. But can in the LC responses differ according to the distance from the anal verge (DAV)? Methods: Exploratory retrospective analyses was planned to evaluate if LC responses differ according to the DAV. LC was defined as tumors originating anywhere from the distal rectum to the left colic flexure (splenic flexure). DAV was describe in cm measured by previous to surgery or treatment, colonoscopy, CT or MRI. Patients were divided for analysis purposes in two groups: Group A (tumors above 12cm from de anal verge), Group B (tumors below 12cm from the anal verge). Results: We retrospectively evaluated 29 patients with left metastatic colorectal cancer treated with anti-EGFR therapy as part of their treatment at the Paulistano Hospital -São Paulo from 2011 to 2018. Median population age 51.8 years (48.5-62.3). Median DAV 14.5 (4.6-25 cm). Median follow-up 12.8 months. No significant difference on stable and partial response rate was detected (Group A 43.7% vs Gropup B 56.3%), p=0.211. Long-rank test with a median pFS 8,5 meses and a PFS at 6 months of 66.7 vs 78,8 (Group A and Group B respectively ), p=0.901. Two-year OS was 58.4 % in Group A and 100% in Group B, p=0.17. Conclusions: Although no significant diferences were detected, responses rates were numerically higher in patients with tumors located below 12 cm from the anal verge. Further studies are needed to evaluate the association between response and DAV.

Download Full-text

Comparison of the anatomical and functional success of fascia and perichondrium grafts in transcanal endoscopic type 1 tympanoplasty

Journal of Otolaryngology - Head and Neck Surgery ◽

10.1186/s40463-019-0386-z ◽

2019 ◽

Vol 48 (1) ◽

Cited By ~ 2

Author(s):

Kadir Özdamar ◽

Alper Sen

Keyword(s):

Retention Rates ◽

Success Rates ◽

Temporal Muscle ◽

Type 1 Tympanoplasty ◽

Significant Difference ◽

The Status ◽

Group A ◽

Group B ◽

Age Range

Abstract Background There are no studies in the literature, comparing the functional and anatomical successes of the use of fascial and perichondrial grafts in endoscopic type 1 tympanoplasties. Objectives To compare the anatomical and functional outcomes of grafting with the fascia of the temporalis muscle and with the perichondrium of the tragal cartilage in patients undergoing primary transcanal type 1 tympanoplasty with endoscopy. Methods We enrolled a total of 151 patients (80 females and 71 males with a mean age of 26.0 ± 9.3 years in the age range between 18-57) with MERI scores ranging from 1 to 3 and who underwent a transcanal endoscopic type 1 tympanoplasty without tympanomeatal flap elevation. The patients were assigned to two groups according to the type of the graft used. The patients were assigned to either the tragal cartilage perichondrium group (Group A) or the fascia of the temporal muscle (Group B). The groups were compared according to the pre- and postoperative air-bone gaps and to the status of the tympanic membrane. Results There were no statistically significant differences in the distribution of the age, gender, localization, MERI scores, the duration of the operation, and the size of the perforation (all p values> 0.05). The pre-operative air-bone gap values of Group A and B did not show a statistically significant difference (p = 0.073). The postoperative improvement in the air-bone gap value did not demonstrate a significant difference between Group A and B (p = 0.202). The graft retention rates were 94.9 and 97.2% in Group A and in Group B respectively. There were no statistically significant differences between the two groups in terms of the graft retention success rates (p = 0.743). Conclusion Perichondrium and fascia were suitable for use in endoscopic tympanoplasties.

Download Full-text

Abstract T MP60: Impact of Aortic Arch Atheroma for Stroke Recurrence in Patients With or Without Atrial Fibrillation

Stroke ◽

10.1161/str.46.suppl_1.tmp60 ◽

2015 ◽

Vol 46 (suppl_1) ◽

Author(s):

Shigeru Fujimoto ◽

Masato Osaki ◽

Masaya Kumamoto ◽

Makoto Kanazawa ◽

Naoki Tagawa ◽

...

Keyword(s):

Atrial Fibrillation ◽

Aortic Arch ◽

Proportional Hazards Model ◽

Cox Proportional Hazards Model ◽

Rank Test ◽

Stroke Recurrence ◽

Significant Difference ◽

Group A ◽

Group B ◽

The Impact

Background & Purpose: In patients with embolic stroke of undetermined source, aortic arch atheroma evaluated using transesophageal echocardiography (TEE) is a possible embolic source. We investigated the impact of embolic sources including aortic arch atheroma for a stroke recurrences and death. Methods: Among the consecutive 1545 acute stroke patients, 542 patients who were admitted within 24 hours after the symptom onset, with ischemic lesions in the cortex or cerebellum on the diffusion-weighted image, NIH stroke scale of 7 or less, and prior modified Rankin scale (mRS) of 0 or 1 were included in the present study. All 542 patients underwent TEE to search for embolic sources. According to the categories of embolic sources, patients were classified into 4 groups: patients with severe aortic arch atheroma of 4mm or more in diameter (group A; n=167), patients with cardiogenic embolic sources such as atrial fibrillation or intracardiac thrombus (group C; n=93), patients with both factors as described above (group B; n=88), and other patients (group O; n=194). We followed them up for average period of 3.2 years, and investigated the frequency of stroke recurrences and death from any cause according to embolic sources. Results: Stroke recurrences were observed in 12.0% patients in group A, 11.8% patients in group C, 18.2% patients in group B, and 6.7% patients in group O respectively (p=0.0371). Stroke recurrences and death from any cause occurred in 14.4%, 15.1%, 21.6% and 6.7% patients respectively (p=0.0041). Kaplan-Meier curve analysis revealed a significant difference in the recurrence-free survival among the four groups (p=0.0076, log-rank test). Stroke recurrence was more frequent in group B than group C patients especially in the early phase from the onset. On COX proportional-hazards model analysis and diabetes mellitus (HR 1.73, p=0.0264) and aortic arch atheroma of 4mm or more (HR 1.86, p=0.0146) were significant predictors for stroke recurrences and death from any cause. Conclusions: Severe aortic arch atheroma can independently be associated with stroke recurrences and death, furthermore, a combination of aortic arch atheroma and cardiogenic embolic sources showed more frequent events than each of them alone.

Download Full-text

Fistula first, graft on arterialized vein second

Vascular ◽

10.1177/1708538114542479 ◽

2014 ◽

Vol 23 (3) ◽

pp. 265-269

Author(s):

Giuseppe Galzerano ◽

Michele Giubbolini ◽

Francesco Setacci ◽

Gianmarco de Donato ◽

Pasqualino Sirignano ◽

...

Keyword(s):

Patency Rate ◽

Rank Test ◽

P Value ◽

Secondary Patency ◽

Kaplan Meier ◽

Significant Difference ◽

Group A ◽

Group B ◽

Vein Stenosis

Objectives Arterovenous grafts (AVGs) present a feasible solution for creating a vascular access in patients who are unsuitable for autogenous fistula (AVF). The aim of this study is to assess the prevention rate of vein stenosis, placing a graft on an arterialized vein (GAV) instead of an anastomized AVG in a native vein (GNV). Methods This was a cohort study conducted from January 2009 to November 2012. All consecutive patients who underwent AVG in our institution were included. All patients requiring a secondary intervention were also referred to our centre. Patients underwent ultrasound follow up at first and the every month. A Kaplan–Meier method was used; a Log-rank test was used to identify whether significant difference existed between GAV and GNV ( p < 0.05). Results Forty-six grafts were placed. Twenty patients had arterialized receiving veins (group A), while 26 patients received an AVG immediately because they lacked autogenous veins suitable for fistula (group B).The average follow-up period was 16.1 months (range 0–41). The group A 41 months-patency rate was 84.3%, while group B was 43.7% ( p = 0.06). Secondary patency was similar in the two groups. Conclusions Vein arterialization seems to prevent venous stenosis improving AVG-patency rate. More data are needed; however, the borderline p value encourages new studies.

Download Full-text

Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors

Breast Care ◽

10.1159/000515729 ◽

2021 ◽

pp. 1-8

Author(s):

Shouko Hayama ◽

Rikiya Nakamura ◽

Toshiko Miyaki ◽

Makiko Itami ◽

Naohito Yamamoto

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Treatment Option ◽

Metastatic Breast ◽

Mtor Inhibitors ◽

Subsequent Treatment ◽

Rank Test ◽

Significant Difference ◽

Group A ◽

Group B

Background/Aims: The study aim was to evaluate if mTOR inhibitors can be considered as a treatment option for HR+ HER2− metastatic breast cancer (MBC) after progression on CDK4/6 inhibitors in clinical practice. Methods: We retrospectively collected the clinicopathological data of patients with HR+ HER2− MBC treated with CDK4/6 inhibitors and subsequent therapies at our institution between 2014 and 2020. The patients were divided into 3 groups according to the type of subsequent treatment: (A) exemestane plus everolimus, (B) endocrine monotherapy, and (C) chemotherapy. Overall survival (OS) was estimated by using the Kaplan-Meier method and compared by using the log-rank test. The efficacy and adverse events (AEs) of each subsequent treatment were assessed by using Fisher’s exact tests. Results: Eighty-six patients (34 in group A, 20 in group B, 32 in group C) were included. The most common endocrine therapy in group B was fulvestrant (40%). The major chemotherapy regimen in group C was eribulin (25%). The median OS times after stopping CDK4/6 inhibitors were 34.5 months (95% confidence interval, 17.2 to NA), 13.6 months (3.9 to NA), and 19.5 months (18.8 to NA) in group A, group B, and group C, respectively. The only significant difference in OS was observed between group A and group B (20.9 months; p = 0.003). There was no difference in the incidence of grade 3 AEs between groups A and C or in the frequency of treatment discontinuation because of AEs among the 3 groups. Conclusion: Our study shows that mTOR inhibitors might be an effective treatment option for patients with HR+ HER2− MBC previously treated with CDK4/6 inhibitors.

Download Full-text

Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival

BMC Neurology ◽

10.1186/s12883-021-02461-9 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Bin Huang ◽

Zuan Yu ◽

Risheng Liang

Keyword(s):

Quality Of Life ◽

Survival Rate ◽

Concurrent Chemoradiotherapy ◽

Patient Survival ◽

Cox Regression Analysis ◽

Significant Difference ◽

Group A ◽

Group B

Abstract Objective Glioblastoma multiforme (GBM) is the most common primary malignant central nervous system (CNS) tumor. The Stupp regimen is the standard treatment, although the optimal number of temozolomide (TMZ) treatment cycles remains controversial. We compared the effects of standard 6 cycles versus > 6 cycles of TMZ chemotherapy post-surgery with concurrent chemoradiotherapy on primary GBM patient survival. Patients and methods We performed a single center retrospective study of GBM patients that underwent total resection, concurrent chemoradiotherapy, and at least 6 cycles of adjuvant TMZ chemotherapy from June 2011 to August 2018. Patients were divided into 2 groups based on adjuvant TMZ treatment plan: Group A(n = 27): standard 6-cycle adjuvant TMZ therapy and Group B(n = 26): > 6 cycles of adjuvant TMZ therapy. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Continuous variables were analyzed by ANOVA, and the Kaplan-Meier method was used to evaluate PFS and OS. Univariate and multivariate COX analyses determined correlation between survival rates and covariates. We used The Mini Mental State Examination (MMSE) and Karnofsky Performance Status (KPS) to assess patients’ neurocognitive function and quality of life. Results After follow-up, median PFS was 15 months in in Group A (95%CI 9.5–20.5) and 20.1 months in Group B (95%CI 15.9–24.4). Group A median OS was 19.4 months (95%CI 15.5–23.2), compared to 25.6 months in Group B (95%CI 20.4–30.8). The 2-year survival rate of Groups A and B was 36% was 66%, respectively (P = 0.02). and 5-year survival was 7% in both. Multivariate COX regression analysis showed association between patient PFS and long-period adjuvant chemotherapy, but not OS. There were no significant difference in disability or quality of life during treatment with Stupp protocol, but differences in MMSE and KPS were in favour of the Groups B after year 1 of the treatment (P < 0.05). Conclusions Long-term adjuvant TMZ chemotherapy was beneficial for PFS and 2-year survival rate in GBM patients, and improved their quality of life contemporarily. But OS was not significantly improved.

Download Full-text